Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy

Seizure

Volumn 18, Issue 2, 2009, Pages 119-123

  Carpay, J A ^a   Aalbers, K ^a   Graveland, G A ^b   Engelsman, M ^c  

^a TERGOOI HOSPITAL   (Netherlands)

^b Epilepsy Center   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Anti epileptic drugs; Chronic epilepsy; Intellectually disabled; Retention rates

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AMINES; ANTICONVULSANTS; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; DRUG UTILIZATION REVIEW; EPILEPSY; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INSTITUTIONALIZATION; MENTAL RETARDATION; MIDDLE AGED; PIRACETAM; RETROSPECTIVE STUDIES; TRIAZINES;

EID: 60649089968     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2008.07.007     Document Type: Article

References (35)

1. Coulter D.L. Epilepsy and mental retardation: an overview. Am J Ment Retard 98 Suppl 1 (1993) 1-11
2. Sunder T.R. Meeting the challenge of epilepsy in persons with multiple handicaps. J Child Neurol 12 Suppl 1 (1997) S38-43
3. Pellock J.M., and Morton L.D. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil 6 (2000) 309-323
4. Coulter D.L. Comprehensive management of epilepsy in persons with mental retardation. Epilepsia 38 Suppl 4 (1997) S24-S31
5. Mattson R.H. The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. Epilepsia 37 Suppl 6 (1996) S45-S53
6. Anonymous. Clinical guidelines for the management of epilepsy in adults with an intellectual disability. Seizure 10 (2001) 401-409
7. Collacott R.A., Dignon A., Hauck A., and Ward J.W. Clinical and therapeutic monitoring of epilepsy in a mental handicap unit. Br J Psychiatry 155 (1989) 522-525
8. Forsgren L., Edvinsson S.O., Blomquist H.K., Heijbel J., and Sidenvall R. Epilepsy in a population of mentally retarded children and adults. Epilepsy Res 6 (1990) 234-248
9. Beavis J., Kerr M., and Marson A.G. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database Syst Rev (2007) CD005399
10. McKee J.R., Sunder T.R., FineSmith R., Vuong A., Varner J.A., Hammer A.E., et al. Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. Epilepsy Behav 4 (2003) 386-394
11. McKee J.R., Sunder T.R., Vuong A., and Hammer A.E. Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. J Child Neurol 21 (2006) 372-379
12. Sunder T.R., McKee J.R., Hammer A.E., and Vuong A. Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. Curr Med Res Opin 22 (2006) 693-702
13. Gidal B.E., Walker J.K., Lott R.S., Shaw R., Speth J., Marty K.J., et al. Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. Seizure 9 (2000) 131-136
14. Kelly K., Stephen L.J., and Brodie M.J. Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy Behav 5 (2004) 878-883
15. Brodtkorb E., Klees T.M., Nakken K.O., Lossius R., and Johannessen S.I. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav 5 (2004) 231-235
16. Arvio M., and Sillanpää M. Topiramate in long-term treatment of epilepsy in the intellectually disabled. J Intellect Disabil Res 49 (2005) 183-189
17. Singh B.K., and White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 11 (2002) 47-50
18. Huber B. Effekte von Topiramat bei Patienten mit Epilepsie und intellektueller Beeinträchtigung [Effects of topiramate in patients with epilepsy and intellectual impairment]. Nervenartz 73 (2002) 525-532
19. Mikati M.A., Choueri R., Khurana D.S., Riviello J., Helmers S., and Holmes G. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 42 (1998) 57-62
20. Crawford P., Brown S., and Kerr M. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 10 (2001) 107-115
21. Bhaumik S., Branford D., Duggirala C., and Ismail I.A. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 6 (1997) 127-133
22. Simister R.J., Sander J.W., and Koepp M.J. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 10 (2007) 336-339
23. Nederlandse Vereniging voor Neurologie, Commissie Kwaliteitsbevordering, Werkgroep Richtlijnen Epilepsie. Richtlijnen Diagnostiek en Behandeling van Epilepsie, Versie; februari 2001 [Dutch Society for Neurology, Commission for Enhancement of Quality, Working Group Guidelines Epilepsy. Guidelines for diagnostics and treatment of epilepsy, version; February 2001].
24. Nederlandse Vereniging voor Neurologie, Werkgroep Richtlijnen Epilepsie. Richtlijnen Diagnostiek en Behandeling van Epilepsie, Herziene, tweede versie; januari 2006 [Dutch Society for Neurology, Commission for Enhancement of Quality, Working Group Guidelines Epilepsy. Guidelines for diagnostics and treatment of epilepsy, revised, second version; January 2006].
25. Huber B., and Tomka-Hoffmeister M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure 12 (2003) 602-603
26. Zaccara G., Messori A., Cincotta M., and Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we lean from long-term studies?. Acta Neurol Scand 114 (2006) 157-168
27. Lhatoo S.D., Wong I.C., Polizzi G., and Sander J.W. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 (2000) 1592-1596
28. Bootsma H.P., Coolen F., Aldenkamp A.P., Arends J., Diepman L., and Hulsman J. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5 (2004) 380-387
29. Lhatoo S.D., Wong I.C., and Sander J.W. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 41 (2000) 338-341
30. Krakow K., Walker M., Otoul C., and Sander J.W. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (2001) 1772-1774
31. Depondt C., Yuen A.W., Bel G.S., Mitchell T., Koepp M.J., Duncan J., et al. The long-term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 77 (2006) 101-103
32. Chung S., Wang N., and Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16 (2007) 296-304
33. Bootsma H.P., Vos A.M., Hulsman J., Lambrechts D., Leenen L., Majoie M., et al. Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 12 (2008) 262-268
34. Bootsma H.P., Ricker L., Diepman L., Gehring J., Hulsman J., Lambrechts D., et al. Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizures 17 (2008) 19-26
35. Sander J.W. New antiepileptic drugs in practice: how do they perform in the real world?. Acta Neurol Scand 181 (2005) 26-29